RNR inhibition reverses FLT3i resistance in AML, prolonging survival

FLT3 ITD+ AML is a particularly aggressive subtype, accounting for a substantial portion of AML cases. These mutations are a major driver of the disease and are consistently associated with inferior clinical outcomes. The advent of FLT3 inhibitors marked a significant step forward, but their efficacy is frequently undermined by the emergence of resistance, leaving many patients with limited treatment options.¹

The underlying mechanism of this acquired resistance often involves the reactivation of the RAS/MAPK signaling pathway, frequently spurred by activating NRAS mutations. This pathway bypasses the FLT3 inhibition, allowing leukemia cells to continue proliferating. Until now, effective strategies to counteract this specific resistance mechanism have been largely absent from the clinical toolkit.¹

Identifying a New Vulnerability

Researchers identified ribonucleotide reductase (RNR) as a critical therapeutic vulnerability in FLT3i-resistant FLT3 ITD+ AML driven by NRAS mutations.¹ RNR is an enzyme essential for DNA synthesis and repair, making it a target in rapidly dividing cancer cells. The study demonstrated that activating RAS signaling, either through SPRY3 loss or oncogenic NRAS mutations, conferred robust resistance to FLT3is in various AML models.¹

Pharmacologic inhibition of RNR using multiple inhibitors, as well as siRNA-mediated RNR suppression, consistently reversed FLT3i resistance. This restored FLT3i sensitivity across multiple FLT3 ITD+ AML models in vitro. This consistent reversal of resistance across different models provides strong evidence for RNR's role in maintaining FLT3i resistance.¹

In Vivo Efficacy and Survival Benefit

The investigators moved from in vitro models to in vivo studies to validate their findings. They tested clofarabine, an FDA-approved RNR inhibitor (RNRi), in combination with FLT3 inhibition. Clofarabine significantly overcame NRAS mutation-driven FLT3i resistance in vivo.¹

In cell line-derived xenograft (CDX) models, the combination of FLT3 inhibition and clofarabine markedly suppressed the progression of FLT3i-resistant AML. This combination also significantly prolonged survival in these models. The efficacy of this combination therapy was further validated in two genetically distinct patient-derived xenograft (PDX) models, both harboring different NRAS mutations. These PDX models demonstrated a robust reduction of leukemia burden, confirming the generalizability of RNR inhibition in primary FLT3i-resistant AML.¹

The consistent results across both CDX and PDX models, particularly with different NRAS mutations, strengthen the argument for RNR inhibition as a broadly applicable strategy. The use of clofarabine, an already approved drug, also streamlines the potential path to clinical translation. Clinicians managing AML patients might find the Oxford Handbook of Clinical Haematology a useful reference for current treatment strategies and emerging therapies in this complex disease.¹

The Mechanism of Action

RNR is responsible for converting ribonucleotides to deoxyribonucleotides, a crucial step in DNA synthesis. By inhibiting RNR, cells cannot produce enough deoxyribonucleotides, leading to DNA damage and replication stress. In the context of FLT3i resistance driven by RAS/MAPK activation, RNR inhibition appears to create a synthetic lethality or at least a significant vulnerability. The exact molecular crosstalk between RAS/MAPK signaling and RNR activity in maintaining FLT3i resistance is complex, but the functional outcome is clear: RNR inhibition cripples the resistant cells.¹

The study did not explicitly detail the precise molecular mechanisms by which RNR inhibition overcomes RAS/MAPK-driven resistance, but the observed restoration of FLT3i sensitivity suggests a direct or indirect interference with the compensatory survival pathways activated by NRAS mutations. This could involve disrupting the increased metabolic demands of resistant cells or interfering with their ability to repair DNA damage induced by other means.¹

Broader Implications for AML Therapy

These findings identify a previously unrecognized therapeutic vulnerability in FLT3i-resistant FLT3 mut+ AML. The establishment of RNR inhibition as an effective strategy provides a strong rationale for the clinical evaluation of RNR inhibitors in combination with FLT3 inhibitors in patients with resistant AML. This could offer a new lifeline for patients who have exhausted standard FLT3i options.¹

The research also highlights the importance of understanding resistance mechanisms at a molecular level. By dissecting how AML cells bypass targeted therapies, investigators can identify new vulnerabilities and develop rational combination strategies. This approach moves beyond simply adding another drug and instead focuses on disrupting the core survival pathways of resistant clones.¹

The study did not provide detailed safety profiles for the clofarabine/FLT3i combination beyond its efficacy in xenograft models. Clofarabine, like other RNR inhibitors, has known toxicities, including myelosuppression, which would need careful management in a clinical setting. The potential for increased toxicity with combination therapy is an obvious caveat that future clinical trials must address.¹

Still, the consistent and robust efficacy observed in both cell line and patient-derived xenograft models, coupled with the use of an FDA-approved agent, positions this strategy for rapid translation. The next step involves moving this combination into early-phase clinical trials to assess safety and preliminary efficacy in human patients.¹

Beyond AML: Other Disease Contexts

While the primary focus was AML, the broader implications of RNR inhibition and RAS/MAPK signaling extend to other cancers. Other research, though not directly linked to FLT3 ITD+ AML, has explored targeted modulation of various signaling pathways in different disease contexts. For instance, modulation of IGFBP5/IGF1, THPO, and P38 MAPK signaling has been investigated as therapeutic strategies for mitochondrial respiratory chain disease and osteosarcoma.² This suggests that understanding fundamental cellular pathways, like RNR activity, can yield insights applicable across a spectrum of diseases.²

Another area of research, while seemingly disparate, underscores the complexity of drug-target interactions and the need for precision. Detergent selection, for example, can significantly influence protein melting behavior and drug-target interaction calling in thermal stability proteomics.³ This highlights the meticulous detail required in preclinical drug development and validation, ensuring that observed effects are robust and reproducible.³

The current study's strength lies in its direct clinical relevance to a specific, high-need patient population. It offers a clear, actionable path forward for patients with FLT3i-resistant AML, a group for whom options are currently limited. The generalizability across different NRAS mutations is particularly encouraging, suggesting that this is not a niche solution but a broader strategy for a common resistance mechanism.¹